← FDA DRUG APPROVALS

FDA ANDA · ANDA215005

ATROPINE SULFATE

atropine sulfate monohydrate

Sponsor: SOMERSET THERAPS LLC

APPLICATION
ANDA215005
TYPE
ANDA
ORIGINAL APPROVAL
2024-11-29
LATEST ACTION
2024-11-29
ROUTE
ENDOTRACHEAL, INTRAMEDULLARY, INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS, INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, INTRAOSSEOUS, ENDOTRACHEAL
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

ATROPINE SULFATEPrescription
ATROPINE SULFATE 8MG/20ML (0.4MG/ML) · SOLUTION · INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, INTRAOSSEOUS, ENDOTRACHEAL

Approval history

2024-11-29UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →